Cart
sales@molnova.com
Delequamine
CAS No. 119905-05-4
Delequamine( —— )
Catalog No. M36152 CAS No. 119905-05-4
Delequamine (RS 15385-197) is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 392 | Get Quote |
|
| 5MG | 615 | Get Quote |
|
| 10MG | 873 | Get Quote |
|
| 25MG | 1270 | Get Quote |
|
| 50MG | 1711 | Get Quote |
|
| 100MG | 2241 | Get Quote |
|
| 500MG | 4437 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDelequamine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDelequamine (RS 15385-197) is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.
-
DescriptionDelequamine (RS 15385-197) is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdrenergic Receptor
-
RecptorAdrenergic Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number119905-05-4
-
Formula Weight350.48
-
Molecular FormulaC18H26N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS(C)(=O)(=O)N1[C@]2(C[C@]3(C=4C(=CC(OC)=CC4)CCN3C[C@]2(CCC1)[H])[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Alfuzosin
Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.
-
ADRA1D receptor anta...
ADRA1D receptor antagonist 1 HCl is an orally active, potent and selective α1D adrenergic receptor antagonist (Ki: 1.6 nM) with potential antiproliferative activity.
-
(S)-(-)-Propranolol ...
(S)-(-)-Propranolol hydrochloride, an adrenergic receptor antagonist, exhibits potential anticancer activity and may enhance the prognosis of burn patients.
